Discovery of a new class of non-β-lactam inhibitors of penicillin-binding proteins with gram-positive antibacterial activity

Journal of the American Chemical Society

Volumn 136, Issue 9, 2014, Pages 3664-3672

  O'Daniel, Peter I ^a   Peng, Zhihong ^a   Pi, Hualiang ^a   Testero, Sebastian A ^a   Ding, Derong ^a   Spink, Edward ^a   Leemans, Erika ^a   Boudreau, Marc A ^a   Yamaguchi, Takao ^a   Schroeder, Valerie A ^a   Wolter, William R ^a   Llarrull, Leticia I ^a   Song, Wei ^a   Lastochkin, Elena ^a   Kumarasiri, Malika ^a   Antunes, Nuno T ^a   Espahbodi, Mana ^a   Lichtenwalter, Katerina ^a   Suckow, Mark A ^a   Vakulenko, Sergei ^a   Mobashery, Shahriar ^a   Chang, Mayland ^a   more..

^a UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; BACTERIA; BIOCHEMISTRY; ENZYME INHIBITION;

ANTI-BACTERIAL ACTIVITY; BACTERIAL STRAINS; BACTERICIDAL ACTIVITY; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MOUSE MODELS; ORAL BIOAVAILABILITIES; OXADIAZOLES; PENICILLIN-BINDING PROTEINS;

PROTEINS;

4 (TERT BUTYLDIMETHYLSILYLOXY)BENZOYL CHLORIDE; 4 PHENOXYBENZONITRILE; 4 [3 [4 [4 (TRIFLUOROMETHYL)PHENOXY]PHENYL] 1,2,4 OXADIAZOL 5 YL]ANILINE; 4 [3 [4 [4 (TRIFLUOROMETHYL)PHENOXY]PHENYL] 1,2,4 OXADIAZOL 5 YL]PHENOL; 4 [4 (TRIFLUOROMETHYL)PHENOXY] N' HYDROXYBENZAMIDINE; 4 [4 (TRIFLUOROMETHYL)PHENOXY]BENZONITRILE; 5 (4 FLUOROPHENYL) 3 [4 [4 (TRIFLUOROMETHYL)PHENOXY]PHENYL] 1,2,4 OXADIAZOLE; 5 [4 (TERT BUTYLDIMETHYLSILYLOXY)PHENYL] 3 (4 PHENOXYPHENYL) 1,2,4 OXADIAZOLE; 5 [4 (TERT BUTYLDIMETHYLSILYLOXY)PHENYL] 3 [4 [4 (TRIFLUOROMETHYL)PHENOXY] PHENYL] 1,2,4 OXADIAZOLE; ANTIBIOTIC AGENT; CIPROFLOXACIN; FOSFOMYCIN; LINEZOLID; N' HYDROXY 4 PHENOXYBENZAMIDINE; NON BETA LACTAM INHIBITOR; OXADIAZOLE DERIVATIVE; PENICILLIN BINDING PROTEIN 2A; RIFAMPICIN; TERT BUTYLDIMETHYLSILYL 4 (TERT BUTYLDIMETHYLSILYLOXY)BENZOATE; TETRACYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL LOAD; BINDING ASSAY; BIOSYNTHESIS; CELL VIABILITY ASSAY; CHROMATOPHORE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SYNTHESIS; ENTEROBACTER; ENTEROCOCCUS FAECIUM; ERYTHROCYTE; ESCHERICHIA COLI; FEMALE; HEMOLYSIS; HOSPITAL INFECTION; IC 50; IN VITRO STUDY; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PERITONITIS; PLASMA CONCENTRATION-TIME CURVE; PSEUDOMONAS AERUGINOSA; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; BIOLOGICAL AVAILABILITY; CELL WALL; COMPUTER SIMULATION; DRUG DISCOVERY; GRAM-POSITIVE BACTERIA; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; OXADIAZOLES; PENICILLIN-BINDING PROTEINS; PROTEIN CONFORMATION;

EID: 84897696562     PISSN: 00027863     EISSN: 15205126     Source Type: Journal    
DOI: 10.1021/ja500053x     Document Type: Article

References (31)

1. Klein, E.; Smith, D. L.; Laxminarayan, R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005 Emerg. Infect. Dis. 2007, 13, 1840-1846
2. Klevens, R. M.; Morrison, M. A.; Nadle, J.; Petit, S.; Gershman, K.; Ray, S.; Harrison, L. H.; Lynfield, R.; Dumyati, G.; Townes, J. M.; Craig, A. S.; Zell, E. R.; Fosheim, G. E.; McDougal, L. K.; Carey, R. B.; Fridkin, S. K. Invasive methicillin-resistant Staphylococcus aureus infections in the United States JAMA, J. Am. Med. Assoc. 2007, 298, 1763-1771
3. Klevens, R. M.; Edwards, J. R.; Tenover, F. C.; McDonald, L. C.; Horan, T.; Gaynes, R. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003 Clin. Infect. Dis. 2006, 42, 389-391
4. Kallen, A. J.; Mu, Y.; Bulens, S.; Reingold, A.; Petit, S.; Gershman, K.; Ray, S. M.; Harrison, L. H.; Lynfield, R.; Dumyati, G.; Townes, J. M.; Schaffner, W.; Patel, P. R.; Fridkin, S. K. Health care-associated invasive MRSA infections, 2005-2008 JAMA, J. Am. Med. Assoc. 2010, 304, 641-648
5. Burton, D. C.; Edwards, J. R.; Horan, T. C.; Jernigan, J. A.; Fridkin, S. K. Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007 JAMA, J. Am. Med. Assoc. 2009, 301, 727-736
6. Overbye, K. M.; Barrett, J. F. Antibiotics: Where did we go wrong? Drug Discovery Today 2005, 10, 45-52
7. French, G. L. Bactericidal agents in the treatment of MRSA infections-The potential role of daptomycin J. Antimicrob. Chemother. 2006, 58, 1107-1117
8. Kaka, A. S.; Rueda, A. M.; Shelburne, S. A., 3rd; Hulten, K.; Hamill, R. J.; Musher, D. M. Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus J. Antimicrob. Chemother. 2006, 58, 680-683
9. Appelbaum, P. C. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus Clin. Microbiol. Infect. 2006, 12 (Suppl 1) 16-23
10. Tsiodras, S.; Gold, H. S.; Sakoulas, G.; Eliopoulos, G. M.; Wennersten, C.; Venkataraman, L.; Moellering, R. C.; Ferraro, M. J. Linezolid resistance in a clinical isolate of Staphylococcus aureus Lancet 2001, 358, 207-208
11. Prystowsky, J.; Siddiqui, F.; Chosay, J.; Shinabarger, D. L.; Millichap, J.; Peterson, L. R.; Noskin, G. A. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci Antimicrob. Agents Chemother. 2001, 45, 2154-2156
12. Silverman, J. A.; Oliver, N.; Andrew, T.; Li, T. Resistance studies with daptomycin Antimicrob. Agents Chemother. 2001, 45, 1799-1802
13. Lewis, J. S., 2nd; Owens, A.; Cadena, J.; Sabol, K.; Patterson, J. E.; Jorgensen, J. H. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy Antimicrob. Agents Chemother. 2005, 49, 1664-1665
14. Talbot, G. H.; Bradley, J.; Edwards, J. E., Jr.; Gilbert, D.; Scheld, M.; Bartlett, J. G. Bad bugs need drugs: An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America Clin. Infect. Dis. 2006, 42, 657-668
15. Enright, M. C.; Robinson, D. A.; Randle, G.; Feil, E. J.; Grundmann, H.; Spratt, B. G. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA) Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 7687-7692
16. Llarrull, L. I.; Fisher, J. F.; Mobashery, S. Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge Antimicrob. Agents Chemother. 2009, 53, 4051-4063
17. Otero, L. H.; Rojas-Altuve, A.; Llarrull, L. I.; Carrasco-Lopez, C.; Kumarasiri, M.; Lastochkin, E.; Fishovitz, J.; Dawley, M.; Hesek, D.; Lee, M.; Johnson, J. W.; Fisher, J. F.; Chang, M.; Mobashery, S.; Hermoso, J. A. How allosteric control of Staphylococcus aureus penicillin-binding protein 2a enables methicillin-resistance and physiological function Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 16808-16813
18. Georgopapadakou, N. H.; Dix, B. A.; Mauriz, Y. R. Possible physiological functions of penicillin-binding proteins in Staphylococcus aureus Antimicrob. Agents Chemother. 1986, 29, 333-336
19. Sauvage, E.; Kerff, F.; Terrak, M.; Ayala, J. A.; Charlier, P. The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis FEMS Microbiol. Rev. 2008, 32, 234-258
20. Fisher, J. F.; Meroueh, S. O.; Mobashery, S. Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity Chem. Rev. 2005, 105, 395-424
21. Wong, K. K.; Pompliano, D. L. Peptidoglycan biosynthesis. Unexploited antibacterial targets within a familiar pathway Adv. Exp. Med. Biol. 1998, 456, 197-217
22. Irwin, J. J.; Shoichet, B. K. ZINC-a free database of commercially available compounds for virtual screening J. Chem. Inf. Model. 2005, 45, 177-182
23. Lim, D.; Strynadka, N. C. Structural basis for the beta lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus Nat. Struct. Biol. 2002, 9, 870-876
24. Boucher, H. W.; Talbot, G. H.; Bradley, J. S.; Edwards, J. E.; Gilbert, D.; Rice, L. B.; Scheld, M.; Spellberg, B.; Bartlett, J. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America Clin. Infect. Dis. 2009, 48, 1-12
25. Miller, A. A.; Bundy, G. L.; Mott, J. E.; Skepner, J. E.; Boyle, T. P.; Harris, D. W.; Hromockyj, K. R.; Marotti, K. R.; Zurenko, G. E.; Munzer, J. B.; Sweeney, M. T.; Bammert, G. F.; Hamel, J. C.; Ford, C. W.; Zhong, W.; Graber, D. R.; Martin, G. E.; Han, F.; Dolak, L. A.; Seest, E. P.; Ruble, J. C.; Kamilar, G. M.; Palmer, J. R.; Banitt, L. S.; Hurd, A. R.; Barbachyn, M. R. Discovery and Characterization of QPT-1, the Progenitor of a New Class of Bacterial Topoisomerase Inhibitors Antimicrob. Agents Chemother. 2008, 52, 2806-2812
26. Fuda, C.; Suvorov, M.; Vakulenko, S. B.; Mobashery, S. The basis for resistance to beta-lactam antibiotics by penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus J. Biol. Chem. 2004, 279, 40802-40806
27. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard, 7 th: document M7-A7 ed., Clinical and Laboratory Standards Institute (CLSI): Wayne PA, 2006.
28. Lorian, V., Ed. Antibiotics in laboratory medicine, 4th ed., Williams & Wilkins: Baltimore, 1996.
29. Xiong, Y. Q.; Bayer, A. S.; Yeaman, M. R. Inhibition of intracellular macromolecular synthesis in Staphylococcus aureus by thrombin-induced platelet microbicidal proteins J. Infect. Dis. 2002, 185, 348-356
30. Zhao, G.; Meier, T. I.; Kahl, S. D.; Gee, K. R.; Blaszczak, L. C. BOCILLIN FL, a sensitive and commercially available reagent for detection of penicillin-binding proteins Antimicrob. Agents Chemother. 1999, 43, 1124-1128
31. Lee, M.; Hesek, D.; Mobashery, S. A practical synthesis of nitrocefin J. Org. Chem. 2005, 70, 367-369